世界の遅発性ジスキネジア（TD）治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Tardive Dyskinesia (TD) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z13625
• 出版社/出版日：GlobalInfoResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療・医薬品

• 販売価格（消費税別）

Single User	￥494,160 (USD3,480)	▷ お問い合わせ
Multi User	￥741,240 (USD5,220)	▷ お問い合わせ
Corporate User	￥988,320 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、遅発性ジスキネジア（TD）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。遅発性ジスキネジア（TD）治療の種類別市場規模（バルベナジン、アマンタジン、テトラベナジン、クロナゼパム、その他）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・遅発性ジスキネジア（TD）治療の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Teva Pharma、Biogen、Johnson & Johnson、GlaxoSmithKline、Neurocrine Biosciences、Pfizer、Novartis、Sanofi、AstraZeneca、Bayer AG
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：バルベナジン、アマンタジン、テトラベナジン、クロナゼパム、その他
・用途別分析2016年-2026年：病院、診療所、その他
・遅発性ジスキネジア（TD）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・遅発性ジスキネジア（TD）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・遅発性ジスキネジア（TD）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・遅発性ジスキネジア（TD）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・遅発性ジスキネジア（TD）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Tardive Dyskinesia (TD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Tardive Dyskinesia (TD) Treatment size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Tardive Dyskinesia (TD) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Tardive Dyskinesia (TD) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Valbenazine
Amantadine
Tetrabenazine
Clonazepam
Others

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Teva Pharma
Biogen
Johnson & Johnson
GlaxoSmithKline
Neurocrine Biosciences
Pfizer
Novartis
Sanofi
AstraZeneca
Bayer AG

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Tardive Dyskinesia (TD) Treatment
1.2 Classification of Tardive Dyskinesia (TD) Treatment by Type
1.2.1 Overview: Global Tardive Dyskinesia (TD) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Type in 2020
1.2.3 Valbenazine
1.2.4 Amantadine
1.2.5 Tetrabenazine
1.2.6 Clonazepam
1.2.7 Others
1.3 Global Tardive Dyskinesia (TD) Treatment Market by Application
1.3.1 Overview: Global Tardive Dyskinesia (TD) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Tardive Dyskinesia (TD) Treatment Market Size & Forecast
1.5 Global Tardive Dyskinesia (TD) Treatment Market Size and Forecast by Region
1.5.1 Global Tardive Dyskinesia (TD) Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Tardive Dyskinesia (TD) Treatment Market Size by Region, (2016-2021)
1.5.3 North America Tardive Dyskinesia (TD) Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Tardive Dyskinesia (TD) Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Tardive Dyskinesia (TD) Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Tardive Dyskinesia (TD) Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Tardive Dyskinesia (TD) Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tardive Dyskinesia (TD) Treatment Market Drivers
1.6.2 Tardive Dyskinesia (TD) Treatment Market Restraints
1.6.3 Tardive Dyskinesia (TD) Treatment Trends Analysis
2 Company Profiles
2.1 Teva Pharma
2.1.1 Teva Pharma Details
2.1.2 Teva Pharma Major Business
2.1.3 Teva Pharma Tardive Dyskinesia (TD) Treatment Product and Solutions
2.1.4 Teva Pharma Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Teva Pharma Recent Developments and Future Plans
2.2 Biogen
2.2.1 Biogen Details
2.2.2 Biogen Major Business
2.2.3 Biogen Tardive Dyskinesia (TD) Treatment Product and Solutions
2.2.4 Biogen Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Biogen Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Product and Solutions
2.3.4 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Product and Solutions
2.4.4 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 GlaxoSmithKline Recent Developments and Future Plans
2.5 Neurocrine Biosciences
2.5.1 Neurocrine Biosciences Details
2.5.2 Neurocrine Biosciences Major Business
2.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Product and Solutions
2.5.4 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Neurocrine Biosciences Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Tardive Dyskinesia (TD) Treatment Product and Solutions
2.6.4 Pfizer Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Tardive Dyskinesia (TD) Treatment Product and Solutions
2.7.4 Novartis Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Tardive Dyskinesia (TD) Treatment Product and Solutions
2.8.4 Sanofi Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 AstraZeneca
2.9.1 AstraZeneca Details
2.9.2 AstraZeneca Major Business
2.9.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Product and Solutions
2.9.4 AstraZeneca Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 AstraZeneca Recent Developments and Future Plans
2.10 Bayer AG
2.10.1 Bayer AG Details
2.10.2 Bayer AG Major Business
2.10.3 Bayer AG Tardive Dyskinesia (TD) Treatment Product and Solutions
2.10.4 Bayer AG Tardive Dyskinesia (TD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Bayer AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Tardive Dyskinesia (TD) Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Tardive Dyskinesia (TD) Treatment Players Market Share
3.2.2 Top 10 Tardive Dyskinesia (TD) Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Tardive Dyskinesia (TD) Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Tardive Dyskinesia (TD) Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Application (2016-2021)
5.2 Tardive Dyskinesia (TD) Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2026)
6.2 North America Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2026)
6.3 North America Tardive Dyskinesia (TD) Treatment Market Size by Country
6.3.1 North America Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2026)
6.3.2 United States Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2026)
7.2 Europe Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2026)
7.3 Europe Tardive Dyskinesia (TD) Treatment Market Size by Country
7.3.1 Europe Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2026)
7.3.2 Germany Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
7.3.3 France Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Market Size by Region
8.3.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Region (2016-2026)
8.3.2 China Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8.3.5 India Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2026)
9.2 South America Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2026)
9.3 South America Tardive Dyskinesia (TD) Treatment Market Size by Country
9.3.1 South America Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Tardive Dyskinesia (TD) Treatment Market Size by Country
10.3.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Tardive Dyskinesia (TD) Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Tardive Dyskinesia (TD) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Tardive Dyskinesia (TD) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Tardive Dyskinesia (TD) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Tardive Dyskinesia (TD) Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Region (2021-2026)
Table 6. Teva Pharma Corporate Information, Head Office, and Major Competitors
Table 7. Teva Pharma Major Business
Table 8. Teva Pharma Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 9. Teva Pharma Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Biogen Corporate Information, Head Office, and Major Competitors
Table 11. Biogen Major Business
Table 12. Biogen Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 13. Biogen Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 15. Johnson & Johnson Major Business
Table 16. Johnson & Johnson Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 17. Johnson & Johnson Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 19. GlaxoSmithKline Major Business
Table 20. GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 21. GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Neurocrine Biosciences Corporate Information, Head Office, and Major Competitors
Table 23. Neurocrine Biosciences Major Business
Table 24. Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 25. Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Pfizer Corporate Information, Head Office, and Major Competitors
Table 27. Pfizer Major Business
Table 28. Pfizer Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 29. Pfizer Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Novartis Corporate Information, Head Office, and Major Competitors
Table 31. Novartis Major Business
Table 32. Novartis Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 33. Novartis Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 37. Sanofi Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 39. AstraZeneca Major Business
Table 40. AstraZeneca Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 41. AstraZeneca Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 43. Bayer AG Major Business
Table 44. Bayer AG Tardive Dyskinesia (TD) Treatment Product and Solutions
Table 45. Bayer AG Tardive Dyskinesia (TD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Tardive Dyskinesia (TD) Treatment Revenue (USD Million) by Players (2019-2021)
Table 47. Global Tardive Dyskinesia (TD) Treatment Revenue Share by Players (2019-2021)
Table 48. Breakdown of Tardive Dyskinesia (TD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Tardive Dyskinesia (TD) Treatment Players Head Office, Products and Services Provided
Table 50. Tardive Dyskinesia (TD) Treatment Mergers & Acquisitions in the Past Five Years
Table 51. Tardive Dyskinesia (TD) Treatment New Entrants and Expansion Plans
Table 52. Global Tardive Dyskinesia (TD) Treatment Revenue (USD Million) by Type (2016-2021)
Table 53. Global Tardive Dyskinesia (TD) Treatment Revenue Share by Type (2016-2021)
Table 54. Global Tardive Dyskinesia (TD) Treatment Revenue Forecast by Type (2021-2026)
Table 55. Global Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021)
Table 56. Global Tardive Dyskinesia (TD) Treatment Revenue Forecast by Application (2021-2026)
Table 57. North America Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Tardive Dyskinesia (TD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Tardive Dyskinesia (TD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Tardive Dyskinesia (TD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Tardive Dyskinesia (TD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Tardive Dyskinesia (TD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Tardive Dyskinesia (TD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Tardive Dyskinesia (TD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Tardive Dyskinesia (TD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Tardive Dyskinesia (TD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Tardive Dyskinesia (TD) Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Tardive Dyskinesia (TD) Treatment Picture
Figure 2. Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Type in 2020
Figure 3. Valbenazine
Figure 4. Amantadine
Figure 5. Tetrabenazine
Figure 6. Clonazepam
Figure 7. Others
Figure 8. Tardive Dyskinesia (TD) Treatment Revenue Market Share by Application in 2020
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Others Picture
Figure 12. Global Tardive Dyskinesia (TD) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Tardive Dyskinesia (TD) Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Region in 2020
Figure 16. North America Tardive Dyskinesia (TD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Tardive Dyskinesia (TD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Tardive Dyskinesia (TD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Tardive Dyskinesia (TD) Treatment Market Drivers
Figure 21. Tardive Dyskinesia (TD) Treatment Market Restraints
Figure 22. Tardive Dyskinesia (TD) Treatment Market Trends
Figure 23. Teva Pharma Recent Developments and Future Plans
Figure 24. Biogen Recent Developments and Future Plans
Figure 25. Johnson & Johnson Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. Neurocrine Biosciences Recent Developments and Future Plans
Figure 28. Pfizer Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Sanofi Recent Developments and Future Plans
Figure 31. AstraZeneca Recent Developments and Future Plans
Figure 32. Bayer AG Recent Developments and Future Plans
Figure 34. Global Tardive Dyskinesia (TD) Treatment Revenue Share by Players in 2020
Figure 35. Tardive Dyskinesia (TD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Tardive Dyskinesia (TD) Treatment Revenue Market Share in 2020
Figure 37. Global Top 10 Players Tardive Dyskinesia (TD) Treatment Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Tardive Dyskinesia (TD) Treatment Revenue Share by Type in 2020
Figure 40. Global Tardive Dyskinesia (TD) Treatment Market Share Forecast by Type (2021-2026)
Figure 41. Global Tardive Dyskinesia (TD) Treatment Revenue Share by Application in 2020
Figure 42. Global Tardive Dyskinesia (TD) Treatment Market Share Forecast by Application (2021-2026)
Figure 43. North America Tardive Dyskinesia (TD) Treatment Sales Market Share by Type (2016-2026)
Figure 44. North America Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2016-2026)
Figure 45. North America Tardive Dyskinesia (TD) Treatment Revenue Market Share by Country (2016-2026)
Figure 46. United States Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Tardive Dyskinesia (TD) Treatment Sales Market Share by Type (2016-2026)
Figure 50. Europe Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2016-2026)
Figure 51. Europe Tardive Dyskinesia (TD) Treatment Revenue Market Share by Country (2016-2026)
Figure 52. Germany Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Tardive Dyskinesia (TD) Treatment Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue Market Share by Region (2016-2026)
Figure 60. China Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Tardive Dyskinesia (TD) Treatment Sales Market Share by Type (2016-2026)
Figure 67. South America Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America Tardive Dyskinesia (TD) Treatment Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Tardive Dyskinesia (TD) Treatment Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Tardive Dyskinesia (TD) Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Tardive Dyskinesia (TD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source

Global Tardive Dyskinesia (TD) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z5550 2021年4月 90Pages
QYResearch社発行の本調査資料では、遅発性ジスキネジア（TD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（バルベナジン、アマンタジン、テトラベナジン、クロナゼパム、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場...

世界の遅発性ジスキネジア（TD）治療市場規模・現状・予測（2021年-2027年）

世界の遅発性ジスキネジア市場規模・現状・予測（2021年-2027年）

Global Tardive Dyskinesia Market Size, Status and Forecast 2021-2027
QYR2104Z5551 2021年4月 99Pages
QYResearch社発行の本調査資料では、遅発性ジスキネジアのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ドーパミン枯渇薬、GABA受容体アゴニスト薬、抗コリン薬）、用途別市場規模（病院、外来手術センター、診断センター）、主要地域別市場規模...

世界の裂肛（切れ痔）治療市場 2021：企業別、地域別、種類・用途別

Global Anal Fissure Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z00859 2021年4月 106Pages
当調査資料では、裂肛（切れ痔）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。裂肛（切れ痔）治療の種類別市場規模（局所ニトログリセリン、カルシウムチャネル遮断薬、便軟化剤、その他）、用途別市場規模（診療所、病院、その他）、地域別市場規模（北米、アメ...

世界の双極性障害・治療市場 2021：企業別、地域別、種類・用途別

Global Bipolar Disorders and Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z02256 2021年4月 101Pages
当調査資料では、双極性障害・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。双極性障害・治療の種類別市場規模（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）、用途別市場規模（病院、薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッ...

世界の骨髄異形成症候群（MDS）治療市場 2021：企業別、地域別、種類・用途別

Global Myelodysplastic Syndrome (MDS) Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z09721 2021年4月 104Pages
当調査資料では、骨髄異形成症候群（MDS）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。骨髄異形成症候群（MDS）治療の種類別市場規模（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス）、用途別市場規模（単系統異形成を伴う難治性血球減少...

世界の強皮症診断・治療市場 2021：企業別、地域別、種類・用途別

Global Scleroderma Diagnostics and Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z12288 2021年4月 108Pages
当調査資料では、強皮症診断・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。強皮症診断・治療の種類別市場規模（コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体...

世界の嚢胞性線維症（CF）治療市場 2021：企業別、地域別、種類・用途別

Global Cystic Fibrosis (CF) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z04114 2021年4月 104Pages
当調査資料では、嚢胞性線維症（CF）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。嚢胞性線維症（CF）治療の種類別市場規模（膵臓酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター）、用途別市場規模（経口薬、吸入薬）、地域別市場規模...

世界の原発性線毛機能不全市場規模・現状・予測（2021年-2027年）

Global Primary Ciliary Dyskinesia Market Size, Status and Forecast 2021-2027
QYR2104Z4788 2021年4月 95Pages
QYResearch社発行の本調査資料では、原発性線毛機能不全のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子検査、電子顕微鏡）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本...

世界のOAB治療市場 2021：企業別、地域別、種類・用途別

Global OAB Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z10131 2021年4月 106Pages
当調査資料では、OAB治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。OAB治療の種類別市場規模（抗コリン作用薬、ミラベグロン、ボトックス）、用途別市場規模（特発性過活動膀胱、神経性過活動膀胱）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、...

世界の遅発性ジスキネジア（TD）治療市場規模・現状・予測（2021年-2027年） Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging…
世界の遅発性ジスキネジア（TD）治療市場規模・現状・予測（2021年-2027年） Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging…
世界の遅発性ジスキネジア市場規模・現状・予測（2021年-2027年） Tardive Dyskinesia (TD) market is estimated to post significant growth in coming years, owing to rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription and increasing incidence of neurological disorders. The key factors driving the growth of the Tardive dyskin…
世界の原発性線毛機能不全市場規模・現状・予測（2021年-2027年） Primary ciliary dyskinesia (PCD), also called immotile ciliary syndrome or Kartagener syndrome, is a rare, ciliopathic, autosomal recessive genetic disorder that causes defects in the action of cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tube…
世界の後天性血友病A治療市場規模・現状・予測（2021年-2027年） ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. Market Analysis and Insights: Global Acquired hemophilia A Treatment Market The global Acquired hemophilia A Treatment market size is projected to reach US$ X…